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Article
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Purpose: Accurate diagnosis of adenoviral conjunctivitis (Ad-Cs) is important for timely
and appropriate patient management to reduce disease transmission. This study
assessed the diagnostic accuracy of a commercially available point-of-care adenovirus
immunoassay and determined whether its predictive accuracy is influenced by signal
intensities of test result bands.
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Methods: Point-of-care immunoassay (AdenoPlus) testing and quantitative polymerase
chain reaction (qPCR) testing was performed on conjunctival swab samples obtained
from eyes of 186 eligible adult participants with presumed infectious conjunctivitis and
symptoms of ≤4 days. Masked observers assessed signal intensities of the immunoassay
test and control bands using densitometry.
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Results: Ad-Cs was confirmed by qPCR in 28 of the 56 eyes that tested positive on the
AdenoPlus, a 50% positive predictive value (95% confidence interval [CI] = 36.9, 63.1). No
adenovirus was detected by qPCR in 128 of 130 eyes that tested negative on AdenoPlus,
a 98.5% negative predictive value (CI = 96.3, 100). Sensitivity and specificity were 93%
(CI = 84.4, 100) and 82% (CI = 76.0, 88.1), respectively. Viral titers significantly correlated
with ratio of test band signal intensities (R2 = 0.32, P = 0.002). Higher positive predictive
value was associated with higher densitometry ratios (receiver operating characteristic
[ROC] area = 0.71; 95% CI = 0.59, 0.83).
Conclusions: Densitometric analyses suggest that the diagnostic accuracy of AdenoPlus is influenced by the signal intensity of the test result bands. Visual comparison of
the test band intensities by clinicians could reduce the false positive rate of point-of-care
immunoassays and aid in the diagnosis of viral infections.
Translational Relevance: Ratiometric densitometry of point-of-care immunoassays
could aid clinicians’ decision making in diagnosing infectious diseases, including Ad-Cs.
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Introduction
Infectious conjunctivitis is a prevalent ocular condition, making up as many as 2% of general practice
consultations.1–3 Viruses, particularly adenoviruses,
are the causative agent in a significant proportion
of conjunctivitis cases,4–7 and there is currently no
US Food and Drug Administration (FDA)-approved
treatment for these ocular infections.8,9 However,
unnecessary or inappropriate prescribing of antibiotics for conjunctivitis is commonplace,10,11 and partly
attributable to the clinical difficulty in discriminating
between viral and bacterial etiologies. In accord, a
meta-analysis concluded that clinicians cannot reliably
differentiate between bacterial and viral conjunctivitis
based on clinical signs and symptoms.12
Rapid antibody tests using lateral flow immunoassays for antigen detection are available to aid clinical diagnoses of viral infections.13 These tests typically
yield a binary “yes/no” result for virus antigen
presence within 15 minutes. The AdenoPlus is one such
immunoassay, using monoclonal antibodies raised
against a conserved adenoviral hexon protein.14 It is
the only FDA-approved point-of-care diagnostic test
for adenoviral conjunctivitis (Ad-Cs).
Diagnostic accuracy is important for the initiation of timely and appropriate clinical management
to reduce transmission, duration, and severity of
Ad-Cs. An initial study of AdenoPlus demonstrated
high positive (94%) and negative (95%) predictive
values,15 although subsequent studies have reported
lower values.16–18 We report a prospective diagnostic
accuracy study to determine the predictive accuracy
of AdenoPlus using quantitative polymerase chain
reaction (qPCR) as comparator. Furthermore, we
determined whether test band signal intensities influence the predictive accuracy of this immunoassay.

Methods
Study Participants
Institutional review board (IRB) approval was
obtained by nine participating clinics and Coordinating Center (Washington University). The study
complied with the ethical principles of the Declaration
of Helsinki and Good Clinical Practices. Adults (age
≥18 years) presenting with red eye(s) and symptom
duration of 4 days or less were invited for eligibility screening. Exclusion criteria included recent ocular
surgery, skin vesicles, corneal dendrites, conjunctival membrane or pseudomembrane, corneal infiltrates,
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corneal ulceration, corneal abrasion, ocular foreign
body, or anterior chamber inflammation. All screened
participants signed informed consent forms after an
explanation of study was provided, and completed a
standardized eye examination that included AdenoPlus
testing. The study reported here was nested within a
National Institutes of Health (NIH)-funded multicenter clinical treatment trial. Participants with positive
AdenoPlus test results were randomized to treatment in
that trial, with conjunctival swab samples being taken at
initial and subsequent follow-up visits to measure viral
load over time.

AdenoPlus Immunoassay and qPCR of
Conjunctival Samples
The point-of-care immunoassay test is referred
to here as the AdenoPlus, which was manufactured and distributed by Rapid Pathogen Screening
(Sarasota, FL) through May 2017 when it was acquired
and distributed by Quidel Corporation (San Diego,
CA). The test was recently renamed the QuickVue
Adenoviral Conjunctivitis Test. Participant enrollment
occurred over a nearly 3-year span, and AdenoPlus
test kits from multiple lots (lot numbers recorded) were
used during study. Sample tests from different lots were
routinely assessed to ensure visible red test lines were
obtained after exposure to adenoviral antigen (positive
control) obtained from Rapid Pathogen Screening.
If both eyes were affected, the first eye affected
was selected as the study eye. If both eyes became
symptomatic on the same day, the study eye was
randomly selected. Study eyes were anesthetized with
one drop of proparacaine 0.5% (Valeant Pharmaceuticals; Bridgewater, NJ) and, after 5 minutes, the AdenoPlus test was performed in accordance with manufacturer’s instructions and a prior report.15 Licensed clinicians applying the test were trained in the procedure prior to the start of the study through practice
sessions and by watching a video demonstration. In
brief (details in Supplementary Methods), the collector
tip was applied to the inferior palpebral conjunctiva 6–
8 times before immersion in provided buffer solution.
After 10 minutes, the AdenoPlus result window was
examined. Presence of a blue control band indicated
test validity; if the blue band was absent, the test was
repeated with a new device. As per the manufacturer’s
directions, clinicians were instructed that the presence
of a red band, however faint, indicated a positive test
for Ad-Cs. Absence of a detectable red band indicated
a negative result.
Inferior palpebral conjunctival swab samples were
obtained 5 minutes after AdenoPlus sampling. The
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swab was placed in Universal Viral Transport medium
(Becton, Dickinson and Company) and frozen at
−80°C within 4 hours of collection. The samples were
shipped on dry ice in batches to the Coordinating
Center where they were stored at −80°C prior to molecular analysis.
For the first 27 study participants, conjunctival
swabs were obtained only from the subset of 11
eyes testing AdenoPlus-positive. These swabs were
immersed in vials containing 3 mL medium and were
analyzed by qPCR concurrently. The Data and Safety
Monitoring Committee then approved the following
modifications to increase rigor of the study protocol: (1) conjunctival swab samples were obtained from
all screened participants (irrespective of AdenoPlus
results); (2) swabs were immersed in vials containing
1 mL medium; and (3) examining clinicians were asked
to photo-document the AdenoPlus results window.
Initially, the purpose of the AdenoPlus photographs
was to enable study personnel to validate clinical
examiners’ decisions on whether the test was positive
or negative. After participant recruitment had ended,
a more quantitative protocol was developed to enable
assessment of the test band signal intensities by masked
observers (see next section).
Frozen conjunctival swab samples were thawed and
nucleic acids were extracted using the NucliSENS
easyMAG system (bioMerieux, Durham, NC). The
LIAISON MDX instrument and adenovirus analytespecific reagents used for real-time qPCR assays were
obtained from Diasorin Molecular LLC (Cypress,
CA). Primers with fluorescein-labeled probes were
used to amplify and detect conserved regions of
the adenovirus hexon gene. Standard curves were
constructed using the Adenovirus Molecular Control
(DiaSorin Molecular LLC) to enable quantification
of viral titers. Details regarding the assay, including
specificity and sensitivity, are in the Supplementary
Methods.

Densitometry of AdenoPlus Immunoassay
Bands
Intensities of AdenoPlus red test bands, relative to
blue control bands, were evaluated by densitometry.
Examining clinicians photographed the results window
of the AdenoPlus, with camera flash on, using their
personal mobile devices (Fig. 1A). Digital images were
uploaded to a centralized study database.
Images were imported into Photoshop (Adobe,
San Jose, CA) and rotated so that the blue control
band formed a straight horizontal line in the top
half. They were then cropped so only the results
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Figure 1. Densitometry of immunoassay bands in AdenoPlus
result window. (A) Example of valid test (blue band visible) that
was deemed positive (red band visible) by the examining clinician.
(B) Image of the cropped result window that was converted to
grayscale. Processed images were always oriented so that bands
were horizontal with blue band top-most. (C) Image brightness was
inverted and maximum mean pixel intensity (MPI) across both bands
was determined. The maximum MPI, obtained at locations denoted
by thin black line, are shown to the right of the image. The red
test-to-blue control band densitometry ratio was calculated to be
(105.1/86.4) = 1.22 in this example.

window was visible, converted to grayscale mode (color
removed; Fig. 1B), and inverted in brightness (Fig. 1C).
Each image was standardized to height by width
dimensions of 5 inches × 3 inches, with 150 pixels/inch
resolution. Contrast and brightness were not adjusted.
Two graders at the Coordinating Center, who were
masked to patient data, AdenoPlus results (assessed
by examining clinicians), and qPCR values, independently performed the densitometry protocol. Using
the “single row marquee” tool, the masked graders
placed the pixel-high marquee line so it spanned across
the top of the blue control band and moved it down
in single-pixel steps until reaching the band bottom,
recording the maximum value for mean pixel intensity
(MPI). The same procedure was repeated for the red
test band if visible. If the red band was not visible, the
maximum MPI at locations between 295 and 305 pixels
below the blue control band was recorded because the
distance between blue and red bands averaged approximately 300 pixels. The MPI across the red test band
area was divided by the MPI across the blue control
band. Thus, a densitometry ratio of 0.5 signifies that
the red test band signal intensity was half as that for
the blue control band (see Fig. 1C). This procedure
was initially validated in a small pilot study in which
the masked observers assessed photographs of AdenoPlus tests that had been treated with adenoviral antigen
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(positive controls; vials obtained from Rapid Pathogen
Screening) or saline (negative controls).
Images flagged by both masked graders as unanalyzable were excluded from further analysis. Flagging
reasons included presence of uneven lighting, shadow,
or dim/bright overall lighting that affected band visibility.

Results
Comparison of AdenoPlus and qPCR Test
Results
There were 212 adults (mean age = 34.5 years ± 15.4
years) presenting with presumed conjunctivitis who
consented to eligibility screening. AdenoPlus testing
and qPCR analyses on conjunctival swab samples
were performed on 186 participants (89%; see Supplementary Results for information on others). Thirty
percent (56 of 186) of eyes tested AdenoPlus-positive,
as judged by the examining clinician, whereas 70% (130
of 186) tested negative. Of eyes testing AdenoPluspositive, 50% (28 of 56) had qPCR-confirmed adenoviral DNA present in the conjunctival swab samples.
For AdenoPlus-negative eyes, 98.5% (128 of 130) were
also negative for adenovirus through qPCR testing
(Table 1). Using qPCR as the gold standard comparator, the AdenoPlus was determined to have sensitivity
of 93.3% and a specificity of 82.1%.
As this study was part of a randomized treatment
trial, follow-up visit data were available for 27 of the
28 eyes that tested positive on AdenoPlus but were
negative for adenovirus by qPCR. In all 27 eyes, qPCR
results were again negative for adenovirus at the next
follow-up visit 1 to 2 days later. These data refute the
possibility of spurious qPCR results and confirm that
negative qPCR results at baseline were repeatable.

Table 1. Number of Eyes Testing Positive (+) or
Negative (−) for Adenovirus by AdenoPlus Immunoassay and qPCR
AdenoPlus +
AdenoPlus −
Total

qPCR +

qPCR −

Total

28
2
30

28
128
156

56
130
186

AdenoPlus parameters: sensitivity = 28/30 = 93.3% (95%
CI = 84.4, 100); specificity = 128/156 = 82.1% (CI = 76.0, 88.1);
positive predictive value = 28/56 = 50% (CI = 36.9, 63.1);
negative predictive value = 128/130 = 98.5% (CI = 96.3, 100).
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Figure 2. Densitometry ratios (red test band-to-blue control band
signal intensities) calculated from images of AdenoPlus test results.
Distribution of ratios obtained from positive (+) and negative (−)
AdenoPlus tests of eyes testing positive or negative for Ad-Cs by
qPCR testing. Lines within each bar represent the median, top, and
bottom of the bar represent the 75th and 25th percentiles, respectively. Whiskers show values for 90th and 10th percentiles and dots
represent remaining outlier points. *P < 0.05, **P < 0.01, KruskalWallis 1-way ANOVA, Dunn’s post hoc.

Densitometry of AdenoPlus Results
Of 186 valid AdenoPlus tests performed, examiners obtained digital images of 142 (76%) tests. Sixteen
images were deemed “unanalyzable” by both masked
graders and excluded from analysis. In total, the
graders calculated red test-to-blue control band densitometry ratios for 126 images with an intraclass correlation of 0.99, indicating high intergrader agreement.
The median densitometry ratios for the images
differed by results on AdenoPlus and qPCR tests (P
< 0.001, 1-way ANOVA). The median ratio for 26
eyes testing positive on both AdenoPlus and qPCR
(0.85, interquartile range [IQR] = 0.73) was higher (P
< 0.001, Dunn’s multiple comparison) than for the
82 eyes (0.68; IQR = 0.30) testing negative on both
tests (Fig. 2). In this latter group, the examining clinician determined the red line was absent in the AdenoPlus results window. The objective densitometry ratios
therefore supported the examiners’ recorded interpretation of AdenoPlus results.
We sought to address whether discordant results
between AdenoPlus and qPCR might be due to
examiner misinterpretation of AdenoPlus results.
Among eyes classified as AdenoPlus-positive, there
were no differences (P = 1.00, Dunn’s) in median
densitometry ratios between qPCR-positive (n = 26;
median = 0.85, IQR = 0.73) and qPCR-negative eyes
(n = 16; median = 0.84, IQR = 0.24). Densitometry
ratios for AdenoPlus-positive and qPCR-negative eyes
were higher (P = 0.019) than for eyes testing negative

Densitometric Analysis of Clinical Immunoassay
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Figure 3. Comparison of densitometry values to quantitative PCR test results. (A) The densitometry ratios (red test-to-blue control band
signal intensities) were significantly correlated to qPCR-determined adenoviral titers (DNA copies per mL) in the samples that were positive
for adenovirus on both AdenoPlus and PCR testing (n = 26; Pearson coefficient = 0.57, R2 = 0.32, P = 0.002). (B) Non-ratiometric raw densitometry values (arbitrary units, 8-bit scale) for the red test bands alone did not significantly correlate to adenoviral titers (Pearson coefficient
= 0.25, R2 = 0.06, P = 0.221) in this same subgroup (n = 26).

on both tests (Fig. 2). Thus, examiner misclassification
of AdenoPlus as an explanation for discordant results
was not supported by these data. There were only
two eyes with negative AdenoPlus but positive qPCR
results (mean densitometry ratio = 0.64), precluding
statistical comparisons with other groups.

Correlation of Densitometry to Adenoviral
Titers
Among eyes testing positive on both AdenoPlus and
qPCR tests (n = 26; Fig. 3A), higher densitometry
ratios correlated with higher adenoviral titers (Pearson
coefficient = 0.57, R2 = 0.32, P = 0.002). This relationship is illustrated by representative images of positive
AdenoPlus tests from eyes with different adenoviral
titers (Fig. 4). The ratiometric methodology was critical in elucidating the correlation, as the signal intensity
of the red bands alone was not significantly (Pearson
coefficient = 0.25, R2 = 0.06, P = 0.221) correlated to
adenoviral titers (Fig. 3B).

Receiver Operating Characteristic Curve
We explored the diagnostic accuracy for Ad-Cs over
the range of AdenoPlus densitometry ratios (Fig. 5).
As the densitometry ratio increases (greater red test
band intensity compared to the blue control band),
AdenoPlus specificity increases, albeit at the expense of
reduced sensitivity. When the red test band signal intensity was 90% of that for the blue control band (ratio =
0.9), the specificity and sensitivity of the test was 0.89
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Figure 4. Representative images, with corresponding densitometry ratios (red-to-blue band signal intensities) and adenoviral titers
(DNA copies per mL), of AdenoPlus test results from eyes that were
(A, B) AdenoPlus positive and qPCR positive, (C) AdenoPlus positive
and qPCR negative, and (D) AdenoPlus negative and qPCR negative.

and 0.46, respectively, and the positive predictive value
increased from 50% to 75% (95% confidence interval
[CI] = 54, 96).

Densitometric Analysis of Clinical Immunoassay

Figure 5. Receiver-operating characteristic (ROC) curve for red
test-to-blue control band densitometry ratios for AdenoPlus results
in the diagnosis of Ad-Cs (n = 124 ratios; n = 26 with qPCR-confirmed
Ad-Cs). Area under the curve was 0.71 (95% CI = 0.59, 0.83), and
was significantly greater than chance with P = 0.001. For ratio = 0.9
(denoted by arrow), sensitivity = 0.46 (CI = 0.27, 0.67), specificity =
0.89 (CI = 0.81, 0.94) and positive predictive value was 75% (CI = 54,
96).

Discussion
The percentage of clinically diagnosed Ad-Cs cases
for which adenoviral etiology is confirmed by PCR
testing is variable, with estimates ranging from 8
to 82%,19–24 highlighting the challenge of accurately
diagnosing Ad-Cs. Although PCR is the gold standard
for adenoviral detection,25,26 the technique is costly and
time-consuming and usually requires off-site testing.
Point-of-care Ad-Cs diagnoses would improve patient
management. Timely diagnoses are also important for
clinical studies on self-limiting pathologies like Ad-Cs,
which typically resolve within 1–2 weeks.27
In this prospective multicenter study, the sensitivity
of AdenoPlus was 93% and the specificity was 82%,
as compared to qPCR testing for adenoviral DNA.
However, for clinicians, the more relevant measure
of diagnostic accuracy may be positive (proportion of positive tests representing true positives) and
negative (proportion of negative tests representing
true negatives) predictive values. Nearly all (128/130)
AdenoPlus-negative eyes also tested negative by qPCR
(98.5% negative predictive value). In contrast, only
half (28/56) of AdenoPlus-positive eyes were also
positive for adenovirus by qPCR (50% positive predictive value).
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Specificity and positive predictive values in this
study are considerably lower than those reported in
four previous studies (Table 2). Reasons for differences
in AdenoPlus performance are not clear. The AdenoPlus exhibited no cross-reactivity with 27 other viral
and bacterial pathogens in laboratory testing,15 but it
is possible that other unidentified pathogens capable of
triggering the immunoassay were present in some eyes.
Another possibility is that AdenoPlus performance
varies depending on adenovirus serotype, although it
was reported to exhibit 100% sensitivity in laboratory
testing with the 12 most common serotypes.15
It is also conceivable that differences in AdenoPlus performance could relate to variances in examiner
criteria used to define AdenoPlus results. The manufacturer’s instructions explicitly direct examiners to
classify AdenoPlus test results as positive if the red
line is detectable, regardless of faintness. To probe
this hypothesis, we developed a protocol for masked
densitometric image analysis of AdenoPlus results.
Similar densitometry approaches have been applied
to molecular biology techniques, such as Western
blotting, in quantifying protein accumulation in signal
bands.28 We found no significant differences in red
test-to-blue control band ratios in the two AdenoPluspositive groups that were either positive or negative for
adenovirus by qPCR. Furthermore, the red test-to-blue
control band ratios were higher in both AdenoPluspositive groups compared to tests from eyes with
negative AdenoPlus and qPCR results (see Fig. 2).
These data indicate that examiner error, meaning
AdenoPlus misclassification, was not a major contributor to lower positive predictive values found in this
study.
In eyes with qPCR-confirmed Ad-Cs, we found
a significant positive correlation between adenoviral
titers and the red test-to-blue control band densitometry ratios (see Fig. 3A). Using a criteria ratio of 0.9 (red
test band 90% as intense as the blue control band), test
specificity and positive predictive value improved (see
Fig. 5). We propose the following simplified decision
tree for clinicians using the AdenoPlus: (1) if the test
is negative (no red band), it is extremely likely that the
patient does not have Ad-Cs; (2) if the red test band is
approximately the same or greater intensity (>90% as
intense) as the blue control band upon visual inspection, it is highly likely that the patient has Ad-Cs; and
(3) if the red test band is significantly less intense than
the blue test band, a definitive diagnosis cannot be
made using AdenoPlus results alone.
Lighting differences between individual images and
across different clinics was a study limitation. Overhead
lighting could have affected the raw signal intensities
for the bands and may have been a contributing factor

TVST | August 2021 | Vol. 10 | No. 9 | Article 30 | 7

Densitometric Analysis of Clinical Immunoassay

Table 2. Comparison of AdenoPlus Performance Parameters Found in Current Study (RAPID) to Results From Four
Prior Studies
Positive Negative
Predictive Predictive
Sensitivitya Specificitya Valuea
Valuea

Location

Sample
Size

RAPID

US

186

93%

82%

50%

99%

Sambursky et al.
201315

US

128

85%

98%

94%

95%

Kam et al.
201516

UK

109

40%

96%

85%

71%

Holtz et al.
201717

US

46

50%

92%

63%

83%

India, US, Sri
Lanka, Brazil

500

X

X

78%

X

b

Lee et al.
201818

% of
Sample
qPCR+

Age in
Years

30/186 Mean 33.8
(16.1%)
range
18–83
34/125
Mean 31
(27.2%)
range
5–90
43/109
Mean 40
(39.4%)
range
16–85
10/46
Mean 29
(21.7%
range
2–65
All: 78% Mean 37
US: 56%
(US)
range

a

Values based on PCR as the comparator.
A positive AdenoPlus test was required for inclusion. Values not available for all parameters because PCR was not performed
on samples from eyes with negative AdenoPlus tests.
b

for the finding that the densitometry of the red test
band alone did not correlate to viral titers (see Fig. 3B).
However, the ratiometric densitometry method helped
to account for differences in lighting during image
acquisition, as dimmer images should result in reduced
raw signal intensities for both bands, with ratio values
remaining relatively stable. The validity of standardizing the red test band intensity as a ratio of the blue
control band intensity was confirmed by its correlation with adenoviral titers, whereas the unstandardized
red band intensities did not correlate with viral titers
(see Figs. 3A vs. 3B). Future studies on the AdenoPlus
should use standardized procedures for photographdocumentation. Point-of-care immunoassays can serve
as important diagnostic tools for clinicians, and the
utility of these tests have gained more public attention
during the coronavirus pandemic that began in 2020.
This ratiometric densitometry protocol utilized in this
study could potentially improve diagnostic accuracy
for other point-of-care virus immunoassays, including
tests that are currently being used in community screenings for coronavirus disease 2019 (COVID-19).29,30
In summary, we found the AdenoPlus point-of-care
immunoassay test to have excellent negative predictive power. This finding has clinical implications, as
negative test results can indicate non-adenoviral etiology to the clinician. However, it had a relatively low
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50% positive predictive power for Ad-Cs using the
manufacturer-recommended criteria of just-detectable
red lines to signify positive tests. Our densitometry analyses suggest that visual comparison of the
test band intensities by clinicians could improve the
diagnostic accuracy of point-of-care immunoassays.
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